DeepMed Research

Meiragtx UK II Ltd.

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: https://www.athena-vision.com

Clinical Trials

Natural History Study for Achromatopsia

Completed

Conditions: Achromatopsia

Interventions: Diagnostic Test: Ocular assessments

First Posted Date: 2019-10-11

Last Posted Date: 2023-06-27

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 85

Registration Number: NCT04124185

Locations: 🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia

Phase 1

Completed

Conditions: Xerostomia Due to Radiotherapy
Head and Neck Cancer
Radiation-Induced Parotid Gland Hypofunction

First Posted Date: 2019-08-02

Last Posted Date: 2023-04-24

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 24

Registration Number: NCT04043104

Locations: 🇺🇸
Leland Stanford Junior University, Stanford, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Gene Therapy for Achromatopsia (CNGA3)

Phase 1

Completed

Conditions: Achromatopsia

Interventions: Biological: adeno-associated virus vector AAV- CNGA3

First Posted Date: 2018-11-29

Last Posted Date: 2022-12-01

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 11

Registration Number: NCT03758404

Locations: 🇺🇸
Kellogg Eye Center, Ann Arbor, Michigan, United States
🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)

Completed

Conditions: Retinitis Pigmentosa

First Posted Date: 2017-11-21

Last Posted Date: 2024-06-20

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 140

Registration Number: NCT03349242

Locations: 🇺🇸
Shiley Eye Institute - UCSD, La Jolla, California, United States
🇨🇦
The Hospital for Sick Children, Toronto, Canada
🇺🇸
Stanford University, Spencer Center for Vision Research, Stanford, California, United States

and more 5 locations

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

Phase 1

Completed

Conditions: Achromatopsia

Interventions: Biological: either AAV - CNGB3 or AAV - CNGA3

First Posted Date: 2017-09-12

Last Posted Date: 2025-04-02

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 34

Registration Number: NCT03278873

Locations: 🇺🇸
Kellog Eye Center, Ann Arbor, Michigan, United States
🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

Phase 1

Completed

Conditions: X-Linked Retinitis Pigmentosa

Interventions: Genetic: AAV2/5-RPGR

First Posted Date: 2017-08-17

Last Posted Date: 2025-01-08

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 49

Registration Number: NCT03252847

Locations: 🇺🇸
Kellogg Eye Center, Ann Arbor, Michigan, United States
🇺🇸
Massachusetts Eye and Ear Institute, Boston, Massachusetts, United States
🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

and more 2 locations

Gene Therapy for Achromatopsia (CNGB3)

Phase 1

Completed

Conditions: Achromatopsia

Interventions: Biological: AAV - CNGB3

First Posted Date: 2016-12-23

Last Posted Date: 2023-03-08

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 23

Registration Number: NCT03001310

Locations: 🇺🇸
University of Michigan Kellog Eye Centre, Ann Arbor, Michigan, United States
🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

Completed

Conditions: Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Leber Congenital Amaurosis (LCA)

Interventions: Biological: AAV OPTIRPE65

First Posted Date: 2016-10-27

Last Posted Date: 2024-04-11

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 15

Registration Number: NCT02946879

Locations: 🇺🇸
Kellogg Eye Center, University of Michigan Health, Ann Arbor, Michigan, United States
🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)

Phase 1

Completed

Conditions: Leber Congenital Amaurosis

Interventions: Biological: AAV RPE65

First Posted Date: 2016-05-24

Last Posted Date: 2021-07-12

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 15

Registration Number: NCT02781480

Locations: 🇺🇸
Kellogg Eye Centre, University of Michigan, Ann Arbor, Michigan, United States
🇬🇧
Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom

Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65

Completed

Conditions: Leber Congenital Amaurosis

First Posted Date: 2016-03-22

Last Posted Date: 2023-08-14

Lead Sponsor: MeiraGTx UK II Ltd

Target Recruit Count: 37

Registration Number: NCT02714816

Locations: 🇺🇸
Kellogg Eye Center, Ann Arbor, Michigan, United States
🇬🇧
Moorfields Eye Hospital, London, United Kingdom

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy